ResultsIQ

ResultsIQ › Latest results › Hester Biosciences Limited

Hester Biosciences Limited Q4 FY26 earnings call summary

NSE: HESTERBIO · BSE: 524669

Earnings call of 15 May 2026, summarised by AI from the filing.

Hester Biosciences Q4 FY26 standalone revenue grew 22% and PAT 174%, with debt reduced to ₹70 cr and Animal Healthcare recovery expected from this quarter.

Key takeaways

  1. Debt reduction Debt reduced to ₹70 cr from ₹102 cr, with debt to equity at 0.19 times.
  2. Poultry growth Poultry Healthcare division grew 41% in Q4 FY26 and 21% in FY26, supported by deeper market penetration and sustained demand.
  3. Raw material costs Increasing raw material costs linked to global geopolitical developments and supply chain disruptions may create periodic cost pressures.

Original filing on BSE

Hester Biosciences Limited Q1 FY27 results

As filed: Revenue ₹77.2 cr (−8% year on year), EBITDA ₹22.8 cr (−1% year on year), PAT ₹96.7 cr (−25% year on year), EBITDA margin 29.5% (+211 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹100 cr (+22% year on year), EBITDA ₹34.3 cr (+81% year on year), PAT ₹16.6 cr (+300% year on year), EBITDA margin 34.3% (+1,000 bps). Score 87 of 100, Above trend. Revenue and profit before exceptional items growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 1000 bps year on year. Tax rate 37%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +12.2% in 28 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹77.4 cr (+23% year on year), EBITDA ₹17.8 cr (+300% year on year), PAT ₹9.3 cr (−15% year on year), EBITDA margin 23.0% (+1,000 bps). Score 71 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 1000 bps year on year. Consolidated profit -15% but standalone +167%. Profit fell 34% from last quarter. Share price after the results: +6.5% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹71.0 cr (−15% year on year), EBITDA ₹11.0 cr (−42% year on year), PAT ₹14.0 cr (+75% year on year), EBITDA margin 15.5% (−713 bps). Score 21 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was above it. EBITDA margin fell 713 bps year on year. Other income 67% of PBT. Consolidated profit +75% but standalone -22%. Revenue fell 15% from last quarter. Profit rose ₹6.0 cr on a year ago, more than the ₹4.0 cr it added the year before. Share price after the results: −2.1% in 30 days (Nifty 500: +0.2%).
  • Q1 FY26: Revenue ₹84.0 cr (+2% year on year), EBITDA ₹23.0 cr (+28% year on year), PAT ₹17.0 cr (+143% year on year), EBITDA margin 27.4% (+543 bps). Score 62 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well above it. EBITDA margin rose 543 bps year on year. Consolidated profit +143% but standalone +0%. Share price after the results: +3.9% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹82.0 cr (+4% year on year), EBITDA ₹19.0 cr (+19% year on year), PAT ₹2.0 cr (−67% year on year), EBITDA margin 23.2% (+292 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well below it. EBITDA margin rose 292 bps year on year. Tax rate 100%. Consolidated profit -67% but standalone +43%. Profit fell 82% from last quarter. Share price after the results: +10.0% in 28 days (Nifty 500: +6.1%).
  • Q3 FY25: Revenue ₹63.0 cr (−6% year on year), EBITDA ₹4.0 cr (−60% year on year), PAT ₹11.0 cr (+175% year on year), EBITDA margin 6.4% (−858 bps). Score 29 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was well above it. EBITDA margin fell 858 bps year on year. Other income 67% of PBT. Consolidated profit +175% but standalone -33%. Revenue fell 25% from last quarter.
  • Q2 FY25: Revenue ₹84.0 cr (+20% year on year), EBITDA ₹19.0 cr (+46% year on year), PAT ₹8.0 cr (+100% year on year), EBITDA margin 22.6% (+405 bps). Score 86 of 100, Above trend. EBITDA margin rose 405 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Hester Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.